Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
about
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosisLong-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
P2860
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Peginterferon beta-1a improves ...... E randomized controlled trial.
@ast
Peginterferon beta-1a improves ...... E randomized controlled trial.
@en
type
label
Peginterferon beta-1a improves ...... E randomized controlled trial.
@ast
Peginterferon beta-1a improves ...... E randomized controlled trial.
@en
prefLabel
Peginterferon beta-1a improves ...... E randomized controlled trial.
@ast
Peginterferon beta-1a improves ...... E randomized controlled trial.
@en
P2093
P2860
P1433
P1476
Peginterferon beta-1a improves ...... E randomized controlled trial.
@en
P2093
Damian Fiore
Douglas L Arnold
Serena Hung
Shifang Liu
Xiaojun You
P2860
P2888
P356
10.1186/S12883-017-0799-0
P577
2017-02-10T00:00:00Z
P6179
1083737838